infliximab   Click here for help

GtoPdb Ligand ID: 5004

Synonyms: cA2 | Inflectra® | Remicade® | Remsima® | SB2 | TA-650 | Zymfentra® (subcutaneous formulation)
Approved drug Immunopharmacology Ligand
infliximab is an approved drug (FDA (1998), EMA (1999))
Compound class: Antibody
Comment: Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 [5].

Biosimilars:
NameTrade nameCompanyClinical PhaseIndicationsReferences
infliximab-dyyb; CT-P13Remsima; Inflectra; FlammegisCelltrion/PfizerApproved (2013 EMA, 2016 FDA)As per reference agent[1-2,8]
infliximab-abda; SB2Flixabi; RenflexisMerck/SamsungBioepisApproved (2016 EMA, 2017 FDA)As per reference agent 
infliximab-qbtx; PF-06438179Ixifi; ZesslyPfizer?SandozApproved (2017 FDA, 2018 EMA)As per reference agent[3]
NI-071 Nichi-Iko PharmaceuticalApproved (2017 Japan); Phase 3 US (NCT02990806)As per reference agent 
BCD-055 BiocadPh 3 (NCT02762838)Rheumatoid arthritis 
Infliximab-EPIRUS; BOW015InfimabEpirus BiopharmaceuticalsApproved (2014 India); Ph 3 US (NCT02683564)Rheumatoid arthritis 
infliximab-axxq; ABP710AvsolaAmgenApproved (2019 FDA)As per reference agent 
STI-002 MabTech/Sorrento Therapeutic   
Infliximab biosimilar 1 Nippon KayakuApproved (Japan 2014)As per reference agent
Two more biosimilars have been approved in Japan: Infliximab biosimilar 2 (Nichi-Iko Pharmaceutical/ Yakuhan Pharmaceutical; 2017) and Infliximab biosimilar 3 (Pfizer Japan; 2018), both indicatated as per reference agent [4].
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: infliximab

Bioactivity Comments
Infliximab has been reported to induce an anti-chimeric antibody response in almost 15% of Crohn's disease patients (47 tested) [6]. This indicates that as predicited, humans can mount an immune response to whole murine variable domains, and is the underlying rationale promoting the development of clinical antibodies with variable domains with more human character (i.e. humanised or fully human monoclonal developments).
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
tumour necrosis factor shed form Primary target of this compound Hs Antibody Binding 8.7 pKd - 5
⤷ pKd 8.7 (Kd 1.8x10-9 M) [5]
Description: Binding affinity of antibody cA2 to recombinant human TNFα